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Liver receptor homolog (LRH-1) is an orphan nuclear receptor (NR5A2) that regulates cholesterol homeosta-
sis and cell plasticity in endodermal-derived tissues. Estrogen increases LRH-1 expression conveying cell
protection and proliferation. Independently, estrogen also protects isolated human islets against cytokine-
induced apoptosis. Herein, we demonstrate that LRH-1 is expressed in islets, including b-cells, and that
transcript levels are modulated by 17b-estradiol through the estrogen receptor (ER)a but not ERb signaling
pathway. Repression of LRH-1 by siRNA abrogated the protective effect conveyed by estrogen on rat islets
against cytokines. Adenoviral-mediated overexpression of LRH-1 in human islets did not alter proliferation
but conferred protection against cytokines and streptozotocin-induced apoptosis. Expression levels of the
cell cycle genes cyclin D1 and cyclin E1 as well as the antiapoptotic gene bcl-xl were unaltered in LRH-1
expressing islets. In contrast, the steroidogenic enzymes CYP11A1 and CYP11B1 involved in glucocorticoid
biosynthesis were both stimulated in transduced islets. In parallel, graded overexpression of LRH-1 dose-
dependently impaired glucose-induced insulin secretion. Our results demonstrate the crucial role of the
estrogen target gene nr5a2 in protecting human islets against-stressed-induced apoptosis. We postulate
that this effect is mediated through increased glucocorticoid production that blunts the pro-inflammatory
response of islets.
INTRODUCTION
Diabetes mellitus is a major global health burden with 3.2
million deaths per year with six deaths attributable to diabetes
or related conditions every minute (1). The disease is charac-
terized by increased blood glucose resulting in secondary com-
plications such as cardiovascular disease, kidney failure,
retinopathy and neuropathy if not properly controlled (2).
Two major etiologies are related to increased glycemia. The
first is an autoimmune destruction of the pancreatic insulin-
producing b-cells (Type 1 diabetes), while the second is
associated with poor b-cell function and increased peripheral
insulin resistance (Type 2 diabetes). Similar to Type 1,
b-cell death is also observed in Type 2 diabetes (3).
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Novel treatment should therefore not only aim at increasing
insulin secretion but also at reducing beta-cell death in the
attempt to maintain a sufficient critical functional b-cell
mass that can normalize blood glucose.
The liver receptor homolog-1 (LRH-1) or NR5A2 is a
member of the Ftz-F1 sub-family of nuclear receptors that
binds as a monomer to its target genes. This nuclear receptor
plays a pivotal role in endodermal development by controlling
expression of key transcription factors, such as Foxa2,
HNF-4a and HNF-1a (4,5). More recently, LRH-1 was also
identified as one of the five transcription factors (together
with Oct4, Sox2, Klf4 and c-myc) capable of reprogramming
murine somatic cells to induced pluripotent stem cells high-
lighting the fundamental function of this orphan nuclear recep-
tor in regulating developmental gene networks (6). In adult
mammals, the nuclear receptor is expressed in the liver (7),
intestine (8) and ovaries (9). In these tissues, LRH-1 regulates
expression of genes involved in cholesterol and bile acid
metabolism as well as steroidogenesis and cell proliferation
(10). LRH-1 is also expressed in the exocrine pancreas
(11,12). Independent studies have failed to detect expression
of LRH-1 in b-cells (11–13). However, a recent study
suggests that LRH-1 is expressed in pancreatic islets (14).
Consistent with this expression pattern, the pancreatic tran-
scription factor PDX1 was shown to regulate LRH-1
expression during development (13). Although LRH-1 is con-
sidered an orphan receptor that possesses constitutive activity,
small phospholipids such as phosphatidylethanolamine were
shown to occupy the ligand pocket domain and to increase
the LRH-1 activity (15). In addition, small bicyclic com-
pounds were recently found to be efficient agonists of
LRH-1 activity (16).
LRH-1 was shown to promote cell proliferation in pancrea-
tic, gastric and hepatic cell lines (8,17). Suppression of LRH-1
by RNA interference provoked apoptosis in the hepatocellular
carcinoma cell line BEL-7402 (18). LRH-1 was also found
to mediate the 17b-estradiol/estrogen receptor a (ERa)-
dependent proliferation/survival of MCF7 cells (19). LRH-1
also conveys a cell protective role by inhibiting inflammatory
responses in the liver as well as in the gut (20,21). These
effects appear to be mediated by the direct transcriptional inhi-
bition of the interleukin (IL)-1b and IL-6 genes by LRH-1
with the concomitant activation of IL-1Ra as well as
CYP11A1 and CYP11B1, two key genes involved in gluco-
corticoid biosynthesis (21,22). Interestingly, isolated human
islets treated with 17b-estradiol were protected against proin-
flammatory cytokine and oxidative stress (H2O2)-induced cell
death (23,24). Furthermore, ERa-deficient mice, independent
of gender, were found to be more susceptible to islet b-cell
apoptosis and prone to insulin-deficient diabetes subsequent
to acute oxidative stress (25).
In view of the reduced b-cell mass in Type 2 diabetes and
destruction of cells in Type 1 diabetes, the identification of
genes conferring replicative and/or protective properties is a
topic of high actuality for the development of cell regeneration
therapy. The apparent capacity of LRH-1 to protect and stimu-
late cell proliferation combined with high expression levels in
human islets provides a strong argument to investigate the
potential implication of this nuclear receptor in b-cell function
and survival. Thus, the present study aims at determining
whether LRH-1 is expressed in the endocrine pancreas and
to evaluate its potential impact on islet physiology. We
show that mouse, rat and human islet b-cells express LRH-1
and that 17b-estradiol through the ERa transiently stimulates
expression of the orphan nuclear receptor. Adenoviral-
mediated overexpression of LRH-1 protects insulin-producing
b-cells from apoptotic agents such as cytokines and streptozo-
tocin, highlighting an unprecedented role of the orphan
nuclear receptor in islet survival.
RESULTS
LRH-1 is expressed in pancreatic islet b-cells
To address the controversy whether LRH-1 is indeed
expressed in pancreatic islet b-cells (11,12,14), we conducted
quantitative RT-PCR (QT-PCR) and immunofluorescence
studies on mouse, rat and human islets. We found that
LRH-1 was expressed in mature rodent and human islets of
Langerhans as well as in fluorescence-activated cell sorting
(FACS)-purified b- and non-b-cells of these islets, albeit at
lower levels than those detected in the control exocrine pan-
creas, liver and intestine samples (Fig. 1A). In contrast, the
heart, kidney and muscle did not show detectable levels of
LRH-1 mRNA. Co-immunofluorescence analysis performed
using anti-LRH-1 and anti-insulin serum confirmed the pres-
ence of endogenous LRH-1 in b- (Fig. 1B) as well as
non-b-cells. In mouse, rat and human dispersed islet cells,
LRH-1 predominantly stained in sub-regions of the nuclei
and cytoplasm. In contrast no staining was detected in both
human and rat islets in the absence of the primary antibody,
suggesting specificity of the anti-LRH-1 sera to the nuclear
receptor (Supplementary Material, Fig. S1A). This premise
was confirmed by western blot analysis performed on total
protein extracts isolated from insulinoma INS-1E cells engin-
eered to conditionally overexpress human LRH-1. Indeed, a
unique specific band corresponding to the estimated molecu-
lar weight of the predominant form of LRH-1 (55 kd) was
detected upon treatment of INS-1E with increasing con-
centrations of doxycycline (DOX) (Supplementary Material,
Fig. S1B). Of note, similar to a recent study we were unable
to detect endogenous LRH-1 by immunoblot analysis (26).
Taken together, these results, clearly demonstrate that the
nuclear receptor is expressed in rodent and human pancreatic
islets and more importantly in the b-cell.
Estradiol stimulates LRH-1 expression via the ERa
but not ERb
In order to investigate the transcriptional regulation of LRH-1
in the endocrine pancreas, islets were exposed to
17b-estradiol, an estrogen derivative shown to transiently
induce the expression of the orphan nuclear receptor and to
promote cell proliferation in the breast cancer MCF7 cell
line (19). LRH-1 transcript levels were transiently increased
in MCF7 and in the insulin-secreting INS-1E cell lines
(Supplementary Material, Fig. S2A and B), as well as in
mouse, rat and human islets reaching maximal induction
after 6 h of exposure to estradiol (approximately 3- and
2-fold in rat and human islets, respectively) (Fig. 2A). No
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differences were detected in estradiol-mediated stimulation of
LRH-1 expression between genders in mouse islets. The
induction was completely abrogated by the addition of the
ER antagonist ICI 182 780 confirming a direct effect of the
estrogen on LRH-1 expression. Of note, LRH-1 transcript
levels were lower in ICI 182-treated islets as compared with
control untreated islets, indicating that the ER signaling
pathway is also involved in maintaining basal LRH-1 tran-
scriptional levels (Fig. 2B). In order to further dissect the
ER-mediated signaling pathway leading to increased LRH-1
expression, rat and human islets were incubated with the
ERa agonist propylpyrazole triol (PPT) or the ERb agonist
diarylpropionitrile (DPN) (Fig. 2B). PPT induced an increase
in LRH-1 mRNA levels similar to the condition with
17b-estradiol, whereas DPN had no significant effect on
LRH-1 transcript levels. To confirm the functional role of
ERa in regulating LRH-1 expression, islets isolated from
ERaKO or ERbKO mice were incubated with 17b-estradiol
(Fig. 2C). Consistent with the pharmacological data, LRH-1
transcript levels were not enhanced in ERaKO islets,
whereas a 3-fold increase was detected in ERbKO as well
as in control littermate islets treated with the hormone. Of
note, although not statistically significant, a decrease in
LRH-1 transcript levels was observed in islets isolated from
ERa ablated transgenic animals suggesting that estrogens
modulate basal levels of the orphan nuclear receptor. Our
results thus show that the ERa-signaling pathway regulates
LRH-1 expression in pancreatic islets.
17b-estradiol protects islets against cytokine-induced
apoptosis partially through LRH-1 stimulation
Estradiol was shown to protect isolated human islets against
cytokine- and oxidative stress-mediated cell death (23,24).
In order to determine whether this effect was conveyed by
LRH-1, siRNA was employed to suppress estrogen-induced
LRH-1 expression in rat islets, which were then exposed to
cytokines. LRH-1 transcript levels were inhibited by 70%
in islets transfected with the LRH-1 siRNA (Fig. 3A). Induc-
tion of LRH-1 by estrogen was completely abrogated in these
islets, whereas scrambled siRNA-expressing islets displayed a
2.5-fold increase in expression of LRH-1 (Fig. 3A). More
importantly, LRH-1 suppression partially sensitized estrogen-
treated islets to cytokine induced-apoptosis (Fig. 3B).
Together, these results demonstrate that estradiol through
ERa induces LRH-1 expression in islets resulting in increased
protection against cytokine-evoked apoptosis.
Adenoviral-mediated overexpression of LRH-1 in islets
does not alter proliferation
In order to gain further insight into the functional impact of
LRH-1 on b-cell physiology, the transcription factor was con-
ditionally overexpressed in islets using tetracycline inducible
adenoviruses. Isolated human islets were co-infected with
Ad-hLRH-1 and Ad-X Tet-On, and incubated for 48 h in the
presence or absence of increasing concentration of the indu-
cing tetracycline analog, doxycycline. QT-PCR established a
dose-dependent stimulation of LRH-1 expression levels,
reaching a 48-fold increase at 1 mg/ml doxycycline as com-
pared with control untreated islets (Fig. 4A). A strong
nuclear immunostaining was detected in 80% of human islet
cells treated with doxycycline, while a diffused nuclear and
cytoplasmic staining was observed in control islets
(Fig. 4B). Similar results were obtained in rat islets as well
as in the insulinoma INS-1E cell line (data not shown). As
LRH-1 was previously shown to stimulate cell replication of
pancreatic LTPA and hepatic FL83B cells (8), we next inves-
tigated the impact of LRH-1 overexpression on islet cell pro-
liferation. Overexpression of LRH-1 did not alter cell
proliferation in rat islets or human islets as compared with
matched controls (Fig. 5).
Figure 1. LRH-1 is expressed in pancreatic islet beta-cells (A) QT-PCR using
RNA purified from isolated mouse, rat and human islets, FACS purified b- and
non-b-cells as well as from various organs were performed to evaluate levels
of LRH-1 transcripts. The average Ct value of LRH-1 for 50 ng of total RNA
isolated from islets was estimated to be 26. Housekeeping genes’ (Rps9 and
cyclophilin) Ct values were approximately 18. Data are presented as fold
change of LRH-1 mRNA levels as compared with islets. ∗∗P , 0.01. N.D.;
not detected. (B) Immunofluorescent detection of LRH-1 (green) and insulin
(red) in dispersed adult mouse, rat and human islets. Nuclei were revealed
using DAPI staining. Merged images confirm nuclear localization of LRH-1.
63× magnification.
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Rat and human islets overexpressing LRH-1 are protected
against cytokine and streptozotocin-induced apoptosis
As a direct relationship between increased LRH-1 expression
and islet survival in the presence of estrogen was observed
(Fig. 2), we next evaluated the potential protective role of
LRH-1 overexpression in rat and human islets exposed to
either cytokines or streptozotocin. In humans, streptozotocin
is used for reducing the size of islet carcinoma, most likely
by increasing b-cell death (27). A 4-fold increase in TUNEL-
positive b-cells was determined in control rat islets cultured in
the presence of cytokines or streptozotocin. Remarkably,
doxycycline-induced LRH-1 expression completely protected
islets against apoptosis (Fig. 6A). Human islet b-cells exhib-
ited a 10-fold increase in cytokine-mediated apoptosis, an
effect that was dose dependently attenuated by increasing con-
centrations of doxycycline (Fig. 6B). LRH-1 overexpressing
human islets were also refractory to apoptosis induced by
Figure 2. 17b-estradiol (E2) stimulates LRH-1 expression in islets via ERa (A) Isolated mouse, rat and human islets were incubated for 6 h with DMSO
(vehicle) or for different times with 10 nM 17b-estradiol. (B) Isolated rat and human islets were incubated for 6 h with 10 nM 17b-estradiol, 100 nM of the
ER antagonist ICI 182 780, the ERa agonist PPT or the ERb agonist DPN. (C) Islets isolated from ERa knockout, ERb knockout or wild type (WT)
sibling mice were incubated for 6 h with DMSO (vehicle) or 10 nM 17b-estradiol. RNA was subsequently isolated and QT-PCR was performed to evaluate
LRH-1 transcript levels. The average Ct value of LRH-1 for 50 ng of total RNA isolated from islets was estimated to be 26. Data are presented as fold
change of LRH-1 mRNA levels as compared with untreated islets.
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elevated doses of streptozotocin (Fig. 6C). As the TUNEL
assay may be prone to false-positive results (28), we also
measured apoptosis by monitoring cytoplasmic nucleosomes,
using a cell death detection ELISA system and found similar
results (Fig. 6D). Taken together these results clearly
suggest that LRH-1 is involved in cell survival rather than
cell proliferation in the endocrine pancreas. Furthermore,
forced expression of LRH-1 recapitulates the effect observed
with 17b-estradiol.
Transcript levels of the steroidogenic genes CYP11A1
and CYP11B1 are specifically increased in LRH-1
overexpressing islets
In an attempt to delineate potential mechanisms by which
LRH-1 enhances b-cell viability, mRNA expression levels
of various target genes were evaluated in islets overexpressing
the orphan nuclear receptor. Consistent with the lack of pro-
liferation, Cyclin D1 and E1 transcript levels were not signifi-
cantly increased in LRH-1 transduced islets (Fig. 7A).
Expression levels of the anti-apoptotic gene bcl-xl also
remained constant (Fig. 7B). In contrast, mRNA levels for
both CYP11A1 and CYP11B1 were increased by 14- and
4.5-folds, respectively, in LRH-1-transduced islets treated
with the highest dose of DOX (Fig. 7C). These two genes
encode cytochrome P450 enzymes, which are implicated
in the generation of cortisol, the main glucocorticoid in
humans (29).
Graded overexpression of LRH-1 attenuates
glucose-induced insulin secretion in human islets
As glucocorticoids were shown to impair glucose-induced
insulin secretion in human islets (30), we sought to determine
whether overexpression of LRH-1 might blunt insulin
secretion in infected islets. Consistent with this premise,
graded overexpression of human LRH-1 resulted in a dose-
dependent decrease in glucose-induced insulin secretion
reaching a maximum inhibition of 60% as compared with non-
treated islets at 1 mg/ml doxycycline (Fig. 8). Similar results
were obtained when secreted insulin levels were normalized
to DNA content rather than to total cellular insulin content
(data not shown).
Figure 3. Targeted repression of LRH-1 abrogates the protective effect of
estrogen on islets. (A) LRH-1 transcript levels were also evaluated by
QT-PCR in rat islets transfected with either 50 nM of LRH-1 targeted
siRNA or scrambled siRNA and incubated with (black bars) or without
(grey bars) 10 nM 17b-estradiol. (B) siRNA-treated rat islets were challenged
with a cocktail of cytokines (2 ng/ml rat IFN-g, IL-1b and TNF-a) in the pres-
ence (black bars) or absence (grey bars) of 10 nM 17b-estradiol. Apoptosis
was then measured using the Cell Death Detection ELISA kit. Data are pre-
sented as percentage of apoptotic enrichment compared with untreated
islets. Each value represents the mean+ s.e. of three independent experiments
performed in triplicates. ∗P, 0.05.
Figure 4. Doxycycline dose dependently increases LRH-1 transcript levels in
human islets infected with Ad-hLRH-1. Human islets were transduced (or not)
with Ad-hLRH-1 and Ad-X Tet-On and cultured in the presence of increasing
concentrations of doxycycline for 48 h. (A) RNA was subsequently isolated
and QT-PCR was performed to evaluate LRH-1 transcript levels. The
average Ct value of LRH-1 for 50 ng of total RNA isolated from islets was
estimated to be 26. Data are presented as fold change of LRH-1 mRNA
levels as compared with untreated islets. Each value represents the mean+
s.e. of three independent experiments performed in duplicate. ∗∗P , 0.01.
(B) Immunofluorescence detection of LRH-1 (green) and insulin (red) as
well as DAPI nuclei staining (blue) in dispersed human islet cells 48 h
after infection with adenoviruses in the presence or absence of 1 mg/ml dox-
ycycline. Merge images confirm nuclear localization of LRH-1. 63× magni-
fication.
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DISCUSSION
Identifying master genes controlling proliferation and survival
pathways may uncover attractive targets for the development
of novel therapies aimed at maintaining adequate b-cell
mass in order to stabilize or even improve glucose metabolism
in diabetic individuals. In this scope, the present study ident-
ifies the orphan nuclear receptor LRH-1 as a new islet tran-
scription factor that conveys increased human islet b-cell
survival in response to insults mimicking diabetes.
Consistent with a recent report (14), we detected the LRH-1
transcript in human and mouse islets and extended these find-
ings to rat islets. Interestingly, Chuang et al. concluded that
LRH-1 was exclusively expressed in a-cells as high levels
were predominantly found in the mouse glucagonoma
a-TC1 cell line while its expression was undetectable in the
insulin-producing MIN6 cell line. However, we clearly
demonstrate expression of LRH-1 in FACS-purified human
and rat b-cells in addition to other islet cell types. Our findings
in mouse islets are in sharp contrast with initial studies indicat-
ing that LRH-1 expression was confined to the exocrine com-
partment of the adult pancreas (11–13). These discrepancies
may stem from different methodological approaches that
allowed detection of low LRH-1 expression levels in mouse
islets by QT-PCR (this study) but not by in situ hybridization
(11,12). Although we cannot eliminate the possibility that islet
preparations were contaminated with residual exocrine tissue
that resulted in the erroneous detection of LRH-1 transcript,
immunocytochemistry clearly established the presence of the
LRH-1 protein in rodent and more importantly in human islets.
These data were substantiated with a second anti-LRH-1 anti-
body reinforcing the concept that LRH-1 is expressed in the
endocrine pancreas and more specifically in b-cells. The
nuclear punctate pattern of LRH-1 detected in human islets
Figure 5. Overexpression of LRH-1 does not induce proliferation in islets.
Proliferation was measured by BrdU incorporation in dispersed rat (A) or
human (B) islets expressing LRH-1. Islets were transduced (or not) with
Ad-hLRH-1 and Ad-X Tet-On, and cultured with or without 1 mg/ml of dox-
ycycline for 48 h. Immunocytochemical detection of BrdU incorporation was
performed 24 h after addition of BrdU (10 mM). Data are presented as percen-
tage of BrdU positive b-cells as compared with the total number of b-cells.
Each value represents the mean+ s.e. of three independent experiments
performed in duplicates.
Figure 6. LRH-1 overexpression protects rat and human islets from either
cytokine- or streptozotocin-induced apoptosis. Isolated rat (A) or human
(B–D) islets were co-infected with Ad-hLRH-1 and Ad-X Tet-On, and cul-
tured in the presence or absence of increasing concentrations of doxycycline
as presented in the bar graph. Islets were subsequently treated for 24 h with
rat (A) or human (B and D) 2 ng/ml IFN-g, IL-1b and TNF-a to induce apop-
tosis. Alternatively, islets were treated with 1 (A, C and D) or 2 mM (C) of
streptozotocin. (A–C) Cell death was measured by the TUNEL assay. Data
are presented as percentage of TUNEL positive b-cells compared with the
total amount of cells. More than 1000 cells were counted for each condition.
(D) Alternatively, apoptosis was measured using the Cell Death Detection
ELISA kit. Data are presented as percentage of apoptotic enrichment com-
pared with untreated islets. Each value represents the mean+ s.e. of three
independent experiments performed in triplicates. ∗P , 0.05; ∗∗P , 0.01.
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is reminiscent of that observed in rat granulosa cells and most
likely stems from sumoylation of the receptor, a process regu-
lated by cAMP signaling (31). Consistent with LRH-1
expression in islets, key pancreatic transcription factors such
as Pdx1, FoxA2 and HNF-1a were shown to regulate
expression of the orphan nuclear receptor during development
and may thus also be involved in modulating expression in
adult islets (13).
We demonstrate that 17b-estradiol stimulates LRH-1 tran-
script levels in human and rodent islets. Pharmacological
studies revealed the functional implication of the ERa but
not ERb in increased LRH-1 expression. Consistent with the
latter, modulation of LRH-1 transcript levels by estrogens
was completely abrogated in ERa-deficient mouse islets.
More importantly, we identify LRH-1 as a downstream
target of the estrogen signaling cascade that results in
improved b-cell survival in the face of physiological stresses
(23,24). Indeed, repression of LRH-1 sensitized estrogen-
treated islets to cytokine-induced apoptosis. Our results
initially appear at odds with a recent report demonstrating
that ERa and b convey their protective effects on islets predo-
minantly via rapid extranuclear mechanisms (24). Nonethe-
less, discrepancies may be resolved by the fact that Liu
et al. performed an acute 5-h stress treatment, which
exposed a rapid non-genomic ER action while we conducted
a chronic 48-h stress treatment that may have revealed a
more long-term ER-mediated transcriptional adaptation to
noxious agents. Consistent with this premise, LRH-1 was
recently shown to up-regulate ER expression in MCF7 cells
suggesting a long-term positive regulatory feedback mechan-
ism between ER and LRH-1 (26). Alternatively, LRH-1
expression levels may be potentially stimulated through the
non-classical membrane-associated ERa rapid signaling
pathway that potentiates gene expression through activation
of extracellular signal-regulated kinases, mitogen-activated
protein kinase and phosphoinositide 3-kinases (32).
The importance of LRH-1 in islet physiology was further
highlighted using an inducible adenoviral vector in which
expression of the orphan nuclear receptor was conditional on
the addition of doxycycline to infected islets. Surprisingly,
overexpression of LRH-1 did not induce cell proliferation in
either rat or human islets. Independent studies have shown
that LRH-1 expression is increased in gastric and breast
cancers and that forced expression facilitates proliferation of
pancreatic LTPA as well as hepatic FL83B cells in synergy
with the b-catenin/TCF7L2 signaling pathway (8,17,19,33).
Failure of causing islet cell proliferation may be a conse-
quence of low expression levels of TCF7L2 and b-catenin in
Figure 7. CYP11A1 and CYP11B1 expression levels are increased in human
islets overexpressing LRH-1. Human islets were infected with Ad-hLRH-1
and Ad-X Tet-On and cultured in the presence of increasing concentrations
of doxycycline for 48 h. Total RNA was then extracted and expression
levels for (A) Cyclin D1 and Cyclin E1 as well as (B) Bcl-xL and (C)
CYP11A1 and CYP11B1 were determined by QT-PCR. Each value represents
the mean+ s.e. of three independent experiments. The average Ct values
of Cyclin D1, Cyclin E1, Bcl-xL, CYP11A1 and CYP11B1 for 50 ng of
total RNA isolated from islets were estimated to be 26, 31, 26, 34 and 30,
respectively.
Figure 8. Graded LRH-1 overexpression impairs glucose-induced insulin
secretion in human islets. Human islets were transduced (or not) with
Ad-hLRH-1 and Ad-X Tet-On and cultured in the presence of increasing con-
centrations of doxycycline for 48 h. Insulin secretion was assessed in 30 min
static incubations in response to 2.5 mM (grey bars) or 16.5 mM glucose
(black bars). Insulin released in KRBH was quantified by EIA and expressed
as a percentage of total cellular insulin content. Results are the mean+ s.e
from three independent experiments performed in triplicates. ∗P , 0.05.
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mature islets, apparently mandatory in LRH-1-mediated cell
replication (34,35). Consistent with the latter, expression
levels of two LRH-1/b-catenin downstream target genes
cyclin D1 and E1 (8) remained constant in LRH-1 expressing
islets.
A major finding of the current work was the capacity of
LRH-1 to protect islets against cytokine- or streptozotocin-
induced apoptosis, two models of experimental diabetes.
Surprisingly, screening of LRH-1-target genes revealed a
robust induction of CYP11A1 and CYP11B1 expression
levels, two transcripts encoding cytochrome P450 enzymes
implicated in the biosynthesis of glucocorticoids. Glucocorti-
coids are potent immunosuppressive agents that blunt
inflammation by inhibiting expression of cytokines with a con-
comitant increase in anti-inflammatory proteins (36). Histori-
cally, glucocorticoids were shown to be diabetogenic and to
hamper islet function in vivo (37,38). These findings led to
their exclusion from immuno-suppressive regimens used sub-
sequent to islet transplantation (39). However, a recent study
demonstrated that exogenous glucocorticoids have potent anti-
inflammatory properties on human islets. Furthermore,
although glucocorticoid-treated human islets exhibited a
rapid reduction in glucose-induced insulin secretion observed
within 24 h, these islets performed considerably better than
control islets in long-term culture (30). Thus, it is tempting
to speculate that LRH-1-mediated b-cell protection against
cytokines could partially be conveyed by increased endogen-
ous production of glucocorticoids resulting in decreased sensi-
tivity of islets to the pro-inflammatory effects of cytokines
with a concomitant impairment in glucose-induced insulin
secretion. Further studies are currently underway to test this
hypothesis. However, mild overexpression of LRH-1
induced by 0.125 mg/ml doxycycline considerably protected
human islets against cytokines without impairing insulin
secretion (Figs 4A, 6B and 8).
In summary, our study reveals LRH-1 expression in human,
mouse and rat b-cells and establishes an unprecedented func-
tion for LRH-1 as a survival factor in these cells. Further
delineating the molecular mechanism implicated in LRH-
1-mediated resistance to apoptotic cues will facilitate develop-
ment of novel therapies for the treatment of diabetes. The
latter approach may prove to be more feasible than attempts
at regeneration in view of recent findings suggesting that
b-cell turnover is limited to the first three decades of human
life (40,41).
MATERIALS AND METHODS
Mice and islet sources
Era and b knockout (KO) mice have been described elsewhere
(42). Animal experiments were performed in accordance with
a Geneva Veterinary Cantonal Office- and a CABIMER-
approved protocol. Pancreatic islets derived from 5-week-old
male Wistar rats, C57BL/6J mice (Elevage Janvier, Le
Genest-St-Isle, France) as well as Era and bKO animals
were isolated by collagenase digestion and hand picked as pre-
viously described (43). Human islets were obtained from
The Cell Isolation and Transplantation Center (Department
of Surgery, Geneva; Switzerland), the Department of
Endocrinology (Metabolism, Metabolic Unit, Cisanello Hospi-
tal, Pisa); Italy and the Cell Therapy for Diabetes-CHRU de
Lille, Lille; France. Islet preparations were washed, hand-
picked and subsequently maintained in CMRL-1066 (Gibco)
containing 5.6 mM glucose supplemented with 10% fetal calf
serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin
and 100 mg/ml gentamycin. b- and non-b-cells were sorted
by FACSVantage SE (Becton Dickenson) as described
previously (44).
Cell line culture
Rat insulinoma INS-1E and MCF7 cells (45) were, respect-
ively, cultured in RPMI-1640 and Dulbecco’s modified
Eagle’s medium (Invitrogen, Basel, Switzerland) sup-
plemented with 10% FCS and other additions as described pre-
viously (46).
Cell treatment
INS-1E cells, MCF7 cells or islets were cultured in phenol
red-free medium containing 10% charcoal-stripped FCS for
48 h. The latter is nearly free of endogenous steroids to
avoid skewing of the results. Islets were then cultured in the
presence of 10 nM 17b-estradiol (Sigma-Aldrich), alone or
in combination with 100 nM ICI 182 780 (ER antagonist;
Tocris Bioscience), 100 nM PPT (ERa agonist; Tocris Bio-
science) or DPN (ERb agonist; Tocris Bioscience). For apop-
tosis studies, islets were exposed to a cocktail of cytokines
(2 ng/ml IFN-g, IL-1b and TNF-a) or streptozotocin (1 mM
if not specified) for 48 h.
RNA interference
Fifty nanomolar of either ON-TARGETplus SMARTpool
siRNA (Dharmacon, Inc., Chicago, USA) targeted to rat
LRH-1 or ON-TARGETplus non-targeting pool was pre-
mixed with Lipofectamine (Invitrogen) and subsequently
exposed to islets for 24 h. Fresh medium was then added
and islets were exposed to cytokines for an additional 48 h.
LRH-1 adenoviral construction and transduction
The full-length human LRH-1 cDNA cloned into the
expression vector pcDNA-T7tag was kindly provided by
Lilly (Hamburg, Germany). Subsequently, LRH-1 cDNA
was subcloned into the pTRE-Shuttle2 vector (CLONTECH
Laboratories, Inc.). The inducible cassette was transferred
into the Adeno-X viral DNA to generate the recombinant
adenovirus Ad-hLRH-1. INS-1E cells were seeded at 3 ×
105 cells/ml in 24-well plates, whereas 150 islets (rat or
human) were used per experimental condition. Cells or
islets were subsequently co-infected with Ad-hLRH-1
along with the adenoviral construct harboring the tetra-
cycline transcriptional activator (Ad-X Tet-On) at a ratio
of 2:1 (3.6 × 107 pfu/ml total viral particles). Cells were
then transferred from 1.7 ml microfuge tubes to 24 well
plates after either 90 min (islets) or 3 h (INS-1E) post-
infection and cultured in fresh media supplemented with
the indicated concentration of doxycycline.
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Quantitative RT-PCR
Total RNA from various organs was extracted using the
RNeasy Micro Kit (Qiagen) and 1–2 mg was converted into
cDNA with the Superscript II Reverse transcriptase (Invitro-
gen). Primers were designed using the Primer Express soft-
ware (Applera Europe, Rotkreuz, Switzerland) and
sequences are provided in Supplementary Material,
Table S1. Real-time PCR was performed using an ABI 7000
Sequence Detection System (Applera Europe), and PCR pro-
ducts were quantified fluorometrically using the FastStart Uni-
versal SYBR Green Master (Roche Diagnostics, Rotkreuz,
Switzerland). Three distinct amplifications were performed
in duplicate for each transcript, and mean values were normal-
ized to the mean value of the reference mRNA cyclophilin
and RPS9.
Immunohistochemistry
Control, treated and transduced islets were trypsinized to
produce a single cell suspension and then cytospinned unto
glass slides. Cells were fixed in 4% paraformaldehyde for
20 min at room temperature. Endogenous and recombinant
LRH-1 were visualized by immunohistochemistry using a
mouse monoclonal antibody against human LRH-1 (Abcam,
Cambridge, UK). Immunochemical detection of b-cells was
performed as previously described (47). Nuclei were stained
with diamidino-2-phenylindole (10 mg/ml; Sigma). Cover
slips were mounted using DAKO fluorescent mounting
medium and visualized using a Zeiss Axiophot I.
Proliferation and apoptosis assays
For proliferation, 10 mM BrdU was added to INS-1E cells for
3 h, and to rat or human islets for 24 h. Proliferation was esti-
mated using an immunohistochemical assay kit as described
by the manufacturer (BrdU labeling and detection Kit,
Roche Diagnostics). Cell apoptosis induced either by cyto-
kines or streptozotocin was measured using the TUNEL
assay (In Situ Cell Death Detection Kit, Roche). Islet cells
were also stained for insulin. Alternatively, the Cell Death
Detection ELISAPLUS (Roche) was used to quantify the
degree of cytoplasmic histone-associated DNA fragments.
Results of BrdU and TUNEL assays are expressed as a percen-
tage of BrdU- or TUNEL-positive b-cells over the total
amount of cells (nuclei staining by DAPI). Results of ELISA
are presented as a percentage of apoptotic enrichment com-
pared with untreated islets.
Glucose-stimulated insulin secretion
Twenty human islets/sample were preincubated with KRBH
buffer (135 mM NaCl, 3.6 mM KCl, 2 mM NaHCO3, 0.5 mM
NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 10 mM HEPES,
pH 7.4 and 0.1% bovine serum albumin) containing 2.5 mM
glucose for 30 min. Cells were then incubated for 30 min in
KRBH buffer containing 2.5 mM glucose and an additional
30 min at 16.5 mM glucose. Insulin content, obtained by
10% acetic acid/ethanol (v/v) treatment of islets, and secreted
insulin were quantified using the rat insulin enzyme immu-
noassay kit (Spi-Bio, Montigny le Bretonneux, France).
Statistical analysis
Results are expressed as mean+SE. Where indicated, the
statistical significance of the differences between groups was
estimated by Student’s t-test. ∗P and ∗∗P indicate statistical
significance with 0.05 and 0.01, respectively.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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